Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 171, Issue 3, Pages 657-666Publisher
SPRINGER
DOI: 10.1007/s10549-018-4862-3
Keywords
Metabolomics; Chemotherapy-induced peripheral neuropathy; Paclitaxel; Breast cancer; Nuclear magnetic resonance
Categories
Funding
- Michigan Institute for Clinical and Health Research (MICHR) KL2 award
- National Institute of General Medical Sciences [NIGMS R01 GM111400]
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000434, KL2TR002241, UL1TR002240] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111400] Funding Source: NIH RePORTER
Ask authors/readers for more resources
PurposeApproximately 25% of breast cancer patients experience treatment delays or discontinuation due to paclitaxel-induced peripheral neuropathy (PN). Currently, there are no predictive biomarkers of PN. Pharmacometabolomics is an informative tool for biomarker discovery of drug toxicity. We conducted a secondary whole blood pharmacometabolomics analysis to assess the association between pretreatment metabolome, early treatment-induced metabolic changes, and the development of PN.MethodsWhole blood samples were collected pre-treatment (BL), just before the end of the first paclitaxel infusion (EOI), and 24 h after the first infusion (24H) from sixty patients with breast cancer receiving (80mg/m(2)) weekly treatment. Neuropathy was assessed at BL and prior to each infusion using the sensory subscale (CIPN8) of the EORTC CIPN20 questionnaire. Blood metabolites were quantified from 1-D-H-1-nuclear magnetic resonance spectra using Chenomx (R) software. Metabolite concentrations were normalized in preparation for Pearson correlation and one-way repeated measures ANOVA with multiple comparisons corrected by false discovery rate (FDR).ResultsPretreatment histidine, phenylalanine, and threonine concentrations were inversely associated with maximum change in CIPN8 (CIPN8) (p<0.02; FDR25%). Paclitaxel caused a significant change in concentrations of 2-hydroxybutyrate, 3-hydroxybutyrate, pyruvate, o-acetylcarnitine, and several amino acids from BL to EOI and/or 24H (p<0.05; FDR25%), although these changes were not associated with CIPN8.ConclusionsWhole blood metabolomics is a feasible approach to identify potential biomarker candidates of paclitaxel-induced PN. The findings suggest that pretreatment concentrations of histidine, phenylalanine, and threonine may be predictive of the severity of future PN and paclitaxel-induced metabolic changes may be related to disruption of energy homeostasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available